Mizuho Reiterates Outperform Rating on Harmony Biosciences Holdings Inc. (HRMY)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Goldman Sachs Reiterates Sell Rating on Harmony Biosciences Holdings Inc. (HRMY)
October 2, 2024 5:37 AM EDTGoldman Sachs analyst Corinne Jenkins reiterated a Sell rating and $28.00 price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY)
The analyst comments "HRMY hosted its Investor Day (10/1) where the focus was on its three neurology franchises, including within (i) sleep/wake, (ii) neurobehavioral, and (iii) epilepsy verticals. The sleep/wake focus was... More
